Edition:
United Kingdom

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
23 Feb 2018
Change (% chg)

$-0.23 (-8.10%)
Prev Close
$2.84
Open
$2.87
Day's High
$2.87
Day's Low
$2.52
Volume
68,185
Avg. Vol
33,846
52-wk High
$12.40
52-wk Low
$2.52

Select another date:

Tue, Feb 20 2018

BRIEF-Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial

* SAYS GOT INDEPENDENT DMC RECOMMENDATION TO CONTINUE PATIENT ENROLLMENT OF ONGOING PHASE 2 CLINICAL TRIAL FOR HS-110 AND NIVOLUMAB​ Source text: (http://bit.ly/2BG2kXt) Further company coverage:

BRIEF-Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial

* SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL

BRIEF-Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​

* Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​

BRIEF-Heat Biologics Inc files for mixed shelf of up to $50 million ‍​

* Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​ Source text - (http://bit.ly/2ltFdsE) Further company coverage:

BRIEF-Heat Biologics sets subscription price of $0.62/shr for its intended rights offering to certain existing security holders

* Says subscription price of $0.62 per share for its intended rights offering to certain of co's existing security holders - SEC filing​ Source text for Eikon: (http://bit.ly/2wZmeaM) Further company coverage:

BRIEF-Heat Biologics been granted type C meeting with FDA

* Heat Biologics- ‍been granted type C meeting with FDA; to discuss registrational pathway for non-small cell lung cancer trial with HS-110 in combination with Bristol Myers' opdivo Source text: (http://bit.ly/2wY2UeW) Further company coverage:

Select another date: